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Available online 30 April 2013Abstract Fanconi anemia patients suffer from progressive bone marrow failure. An overactive p53 response to DNA damage
contributes to the progressive elimination of Fanconi anemia hematopoietic stem and progenitor cells (HSPC), and hence presents
a potential target for therapeutic intervention. To investigate whether the cell cycle regulatory protein p21 is the primary
mediator of the p53-dependent stem cell loss, p21/Fancd2 double-knockout mice were generated. Surprisingly double mutant
mice displayed even more severe loss of HSPCs than Fancd2−/− single mutants. p21 deletion did not rescue the abnormal cell cycle
profile and had no impact on the long-term repopulating potential of Fancd2−/− bone marrow cells. Collectively, our data indicate
that p21 has an indispensable role inmaintaining a normal HSPC pool and suggest that other p53-targeted factors, not p21,mediate
the progressive elimination of HSPC in Fanconi anemia.
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blood count; KSL, cKit+Sca1+Lin−; FITC, fluorescein isothiocyanate;
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Bone marrow failure is the primary cause of early mortality
for FA patients (Kutler et al., 2003). It has been reported that
a subset of FA patients with lower levels of CHK1 and p53
expression and abrogation of the G2 cell cycle checkpoint
display much milder bone marrow deficiency (Ceccaldi et al.,
2011). Further mechanistic studies established that an over-
active p53 response to cellular stress and DNA damage drives
the progressive elimination of hematopoietic stem and progen-
itor cells (HSPC) in FA patients, suggesting p53 down-regulation
as a potential target for FA drug design (Ceccaldi et al., 2012).
Figure 1 p21 deletion reduced KSL pool but did not change stem cell function. (A) Quantification of KSL hematopoietic stem and
progenitor cell frequencies in the bone marrow of Fancd2−/−/Cdkn1a−/− mice and controls. The percentage of the KSL gate refers to
the proportion of KSL cells in the whole nucleated bone marrow. n = 8 for Fancd2+/+/Cdkn1+/+ mice, n = 11 for Fancd2+/+/Cdkn1a−/−
mice, n = 8 for Fancd2−/−/Cdkn1+/+ mice, and n = 10 for Fancd2−/−/Cdkn1a−/− mice. (B, C) Cell cycle profiles of bone marrow KSL
cells. n = 9 for Fancd2+/+/Cdkn1+/+ mice, n = 9 for Fancd2+/+/Cdkn1a−/− mice, n = 7 for Fancd2−/−/Cdkn1+/+ mice, and n = 9 for
Fancd2−/−/Cdkn1a−/− mice. NS denotes not significant. (D) Upper panel: Strategy used in the competitive repopulation experiment.
BMCs denotes bone marrow cells. Lower panel: In vivo competitive repopulation of Fancd2−/−/Cdkn1a−/− (or control) donor and
ROSA26Tg/O bone marrow cells. qPCR analyses were performed to evaluate donor contribution to the peripheral blood cells from each
donor. Three independent qPCR analyses were performed for each sample and results from 5 animals were pooled together for each
experimental group. Data are presented as mean ± SD. NS denotes not significant.
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both FA mouse models and human FA patients (Ceccaldi et al.,
2011; Houghtaling et al., 2005; Freie et al., 2003). Given the
detrimental tumorigenic effects of p53 loss, it is desirable
to shut down only those p53-target genes specifically involved
in HSPC elimination in FA. Further understanding the molecular
targets of p53-mediated HSPC elimination could guide the
future design of therapeutic regimens exploiting this approach.
p21, encoded by the Cdkn1a gene, is a key p53-target gene and
the main factor responsible for p53-mediated cell cycle arrest
and apoptosis (Abbas and Dutta, 2009). p21 could even be the
sole mediator of the overactive p53 response to DNA damage
in FA HSPC, pointing to p21 inhibition as a way to prevent the
progressive HSPC loss in FA (Murray et al., 2010; Sax et al.,
2002). Interestingly, p21 deletion is already known to rescue
stem cell self-renewal from mice suffering from DNA damage
provoked by dysfunctional telomerase (Choudhury et al., 2007).
On the other hand, it has also been reported that p21 has an
important role in the regulation of FA-BRCA pathway activation(Rego et al., 2012). Therefore, the precise outcome of p21
deletion in FA patients warrants further investigation.
Fancd2−/− mice on the 129S4 genetic background
recapitulate major FA patient phenotypes, displaying tumor
susceptibility and hematopoietic defects (Houghtaling et al.,
2003; Zhang et al., 2010). Here we characterized p21 and
Fancd2 double-knockout mice to understand whether p21
is involved in the FA pathway and whether the rescue effects
of p53 deletion on HSC maintenance are p21-related.Methods
Mice
Fancd2 and ROSA26 transgenic mice were maintained on the
129S4 background. Cdkn1a deficient mice were originally
ordered from Jackson Laboratories (Bar Harbor, Maine)
and backcrossed to the 129S4 background for more than 10
Figure 2 Representative flow cytometry profile of cell cycle analysis. p21 deletion did not change the abnormal cell cycle status of
Fancd2−/−mice. Hoechst 33342 and FITC-conjugated anti-mouse Ki67 (BD Sciences) were used in combination to distinguish cells in G0, G1,
and S-G2-M phases of the cell cycle.
689Fancd2 and p21 work independently in hematopoiesisgenerations (Brugarolas et al., 1995). Heterozygotes were
crossed inter se to generate mutant mice and littermate
controls. All mice used were 4 months old. All animals were
treated in accordance with the guidelines of the Institutional
Animals Care and Use Committee.
Complete blood count (CBC)
Comprehensive CBC tests were measured by IDEXX Laboratories
to monitor hematological parameters.
Histopathology
Testis sections were fixed in 10% phosphate-buffered formalin
and stained with hematoxylin and eosin (H&E) as reported
previously (Zhang et al., 2008).
Flow cytometry
Bone marrow cells were isolated from Fancd2−/−/Cdkn1a−/−
mice and littermate controls, immunostained, and analyzed by
flow cytometry, as previously described (Zhang et al., 2010).In vivo competitive repopulation assay
Competitive repopulation assays were done as previously
described (Zhang et al., 2010). Briefly, donor bone marrow
cells were isolated from Fancd2−/−/Cdkn1a−/− mice (or
littermate controls) and ROSA26Tg/O mice. Test donor cells
were mixed with ROSA26Tg/O bone marrow cells at a 1:1 ratio
and then transplanted into lethally irradiated Fancc−/−
recipient mice. Quantitative real-time PCR (qPCR) analysis
of the peripheral blood was performed 6 months after
transplantation.
Statistical analysis
Two-tailed, unpaired Student's t-tests were performed to cal-
culate P values using Prism 4.0 software (GraphPad Software
Inc). A P value less than 0.05 was considered significant.
Results and Discussion
We reported previously that Fancd2−/− mice have readily de-
tectable hematopoietic defects, including fewer cKit+Sca1+Lin−
(KSL) hematopoietic stem and progenitor cells, compromised
Figure 3 Representative pictures after H&E staining of testis sections. p21 deletion did not correct the germ-cell-loss phenotype of
Fancd2−/− mice. The mice used were 4 months old. The arrows indicate tubules with vacuolated Sertoli cell cytoplasm. Original
magnification ×100.
Figure 4 p21 deletion did not affect hematologic parameters of peripheral blood. Comprehensive CBC tests of peripheral blood
from Fancd2−/−/Cdkn1a−/− mice and controls. n = 11 for Fancd2+/+/Cdkn1+/+ mice, n = 15 for Fancd2+/+/Cdkn1a−/− mice, n = 9
for Fancd2−/−/Cdkn1+/+ mice, and n = 11 for Fancd2−/−/Cdkn1a−/− mice. WBC denotes white blood cells; RBC, red blood cells; HGB,
hemoglobin; and NS, not significant. Unless specified otherwise on the figure, P values were not significant.
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691Fancd2 and p21 work independently in hematopoiesisHSC repopulating capacity, and abnormal cell cycle status of
KSL cells (loss of quiescence and increased cycling) (Zhang et
al., 2010). To determine whether lack of p21 has an impact on
any of these parameters in Fancd2−/− mice, we characterized
hematopoietic phenotypes of Fancd2−/−/Cdkn1a−/− mice first
by measuring the size of their KSL pool. As compared to
wild-type controls, both Fancd2−/− mice and Cdkn1a−/− mice
suffered a significant reduction in the size of the KSL HSPC pool
(Fig. 1A). Fancd2−/−/Cdkn1a−/− mice had the smallest HSPC
population among the different genotypes. This observation
indicates that p21 and Fancd2 deletion independently cause
loss of hematopoietic stem and progenitor cells, suggesting
that both Fancd2 and p21 are important for maintaining the
normal size of HSPC pool.
The ability to maintain quiescence is critical for HSC
function (Orford and Scadden, 2008). Considering that p21 is
an important cell cycle regulator, we next analyzed the cell
cycle profiles of Fancd2−/−/Cdkn1a−/− KSL cells. As shown in
Figs. 1B, C and 2, p21 deficiency did not significantly correct
the abnormal cell cycle status of Fancd2−/− KSL cells.
To further assess how Fancd2−/−/Cdkn1a−/− HSCs perform
functionally in a stressful environment, we next performed
in vivo competitive repopulation assays, in which test
donor bone marrow cells competed with wild-type bone
marrow bearing the ROSA26Tg/O marker. We transplanted
equal numbers of nucleated whole bone marrow cells into
each lethally irradiated recipient and analyzed the recipient
mice 6 months after transplantation. Fancd2−/−/Cdkn1a−/−
bone marrow cells performed similarly to their single mutant
Fancd2−/− counterparts (Fig. 1D). This is in stark contrast to the
effect of p53 deletion, which significantly enhanced hemato-
poietic stem cell activity in Fancd2−/− mice (Ceccaldi et al.,
2012). Since Fancd2−/− mice show germ cell loss (Houghtaling
et al., 2003), we further examined whether p21 deletion would
have any impact on this phenotype. As shown in Fig. 3, testes
from both Fancd2−/− mice and Fancd2−/−/Cdkn1a−/− mice
displayed tubules with vacuolated Sertoli cell cytoplasm and
decreased numbers of spermatocytes and spermatids, once
again demonstrating a lack of substantial rescue by p21 loss.
We also performed complete blood counts from 4-month
old Fancd2−/−/Cdkn1a−/− mice and controls. Hematologic
parameters of Cdkn1a−/− mice were slightly higher than
those of wild-type mice (Fig. 4). However, the changes
were insignificant. Overall Fancd2−/−/Cdkn1a−/− double
mutant mice showed the worst hematopoietic parameters
such as lowest platelet counts among all four genotype groups
tested.
In summary, we observed that p21 deficiency did not rescue
any of themajor hematopoietic phenotypes of Fancd2−/−mice,
such as abnormal cell cycle status of HSPC and long-term
repopulating potential. To the contrary, p21 deletion caused a
further reduction in the HSPC pool. These results are in clear
contrast to the obvious rescue effects from p53 deletion in
mice on the same genetic background (Ceccaldi et al., 2012)
and argue against the possibility that p21 functions as a primary
mediator of p53-driven HSPC elimination in FA. Clearly other
factors regulated by p53 play a more important role. It is
noteworthy that p21 depletion in FA patient HSPCs is able to
rescue their clonogenic growth defects (Ceccaldi et al., 2012).
This discrepancy to our in vivo results may be partly due to the
differences in the p53-mediated responses between human
and mice. It is also possible that an acute knockdown of p21may provide temporary benefits to hematopoiesis but that
this is not sustained over time.
It has been under debate whether p21 is involved in normal
HSC function (Tesio and Trumpp, 2011). In this study, we also
uncovered an indispensable role of p21 in maintaining the
normal size of the HSPC pool in 129S4 mice. This novel role
was not seen in previous studies using p21 murine models
on other genetic backgrounds (Cheng et al., 2000; van Os
et al., 2007). Further investigation is needed to reconcile
these discrepancies.
Key points1 Hyperactive p53 activity causes stem cell loss in Fanconi anemia
mice. But this process is not mediated by its main target p21.
2 Both Fancd2 and p21 are important for maintaining the normal size
of HSPC pool. The two proteins work independently in this function.Authorship
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